Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. Homo sapiens

To identify the gene signature accounting for the distinct clinical outcomes in ovarian clear cell cancer patients Clear cell ovarian cancer is an epithelial ovarian cancer histotype that is less responsive to chemotherapy and carries poorer prognosis than serous and endometrioid histotypes. Despite this, patients with these tumors are treated in a similar fashion as all other ovarian cancers. Previous genomic analysis has suggested that clear cell cancers represent a unique tumor subtype. Here we generated the first whole genomic expression profiling using epithelial component of clear cell ovarian cancers and normal ovarian surface specimens isolated by laser capture microdissection. Arrays analyzed using BRB ArrayTools and PathwayStudio software was used to identify the signaling pathways. Overall design: Gene expression profiling was completed for 10 clear cell ovarian cancer specimens and 10 normal ovarian surface epithelium using the Affymetrix human U133 Plus 2.0 Arrays

为明确卵巢透明细胞癌患者临床结局异质性相关的基因特征，本研究首先明确：卵巢透明细胞癌属于上皮性卵巢癌（epithelial ovarian cancer）组织学亚型（histotype），其化疗响应率低于浆液性（serous）与子宫内膜样（endometrioid）组织学亚型，且预后更差。尽管如此，此类肿瘤患者的治疗方案仍与其他卵巢癌患者保持一致。既往基因组分析提示，透明细胞癌属于一类独特的肿瘤亚型。本研究首次采用激光捕获显微切割（Laser Capture Microdissection）分离的卵巢透明细胞癌上皮组分与正常卵巢表面组织标本，开展全基因组表达谱分析。本研究使用BRB ArrayTools及PathwayStudio软件对基因芯片数据进行分析，以鉴定相关信号通路。实验整体设计：本研究采用Affymetrix人类U133 Plus 2.0基因芯片，对10例卵巢透明细胞癌标本与10例正常卵巢表面上皮标本完成基因表达谱检测。